Nitrosamine Impurities-Aug 2023 NDSRIs Limit USFDA Guidance | Control of Nitrosamine Guidance Feb-21
Nitrosamine Impurities - Comprehensive Presentation | USFDA Guidance for Control (Feb-2021) | Limit for NDSRI (Aug-2023) The presentation describes the details of Nitrosamines, their control limits and the determination of AI limit for NDSRIs. #Nitrosamine impurities #Nitrosamine impurities FDA Guidance #Nitrosamine impurities NDSRI Guidance Aug 2023 #USFDA Guidelines #pharmaceutical Your Queries: Nitrosamine impurities Nitrosamine impurities FDA Guidance Nitrosamine Structure Nitrosamine drug substance related impurities Acceptable limit for Nitrosamine impurities Step-1 Risk Assessment for Nitrosamines Step-2 Confirmatory testing for Nitrosamines Step-3 Submitting changes to FDA for Nitrosamines Pharmaceutical Guidelines Pharmaceutical Guidance Documents USFDA Guidelines for Pharmaceuticals Pharma Guidelines for Nitrosamines Pharma Guidelines About the Channel: The channel provides details of pharmaceutical guidelines, important updates on pharmaceuticals and other professional topics like interview preparation, personality development etc. Contact us at: shanu4777@gmail.com https://www.facebook.com/ProfTalks1680 https://www.linkedin.com/groups/13995930/ Subscribe to our channel for more informative videos: https://www.youtube.com/channel/UCis3Rsw8ev1d68OC1prwiNQ 0:00 Introduction and overview 3:27 The sartan story 5:39 The ranitidine story 6:29 The metformin story 7:33 Nitrosamine impurity guidance 10:30 Root causes in APIs 15:12 Sources other than APIs 16:54 Acceptable intake limits 18:55 API manufacturer recommendations 21:46 Drug product recommendations 23:04 Supply and reporting 24:27 Implementation timelines 25:37 NDSRIs overview 27:47 NDSRI determination challenges 28:54 Carcinogenic potency approach 30:20 Potency categories 31:26 Decision tree for categorization 33:46 Calculating potency score 36:42 Potency score examples 38:51 Multiple nitrosamine recommendation 40:21 NDSRI risk in APIs 41:12 NDSRI implementation timeline 42:52 Justification and mutagenic assessment
Suggested videos

Stability Study ICH Guidelines Q1A, Q1B & Q1C | Stability approach | Stress testing | Photostability
ProfTalks · 47:39

GDF2025 - D2S02- Nitrosamine Related Guidance
U.S. Food and Drug Administration · 21:48

Revised ICH Q9 (R1) Quality Risk Management Guideline | Jan 2023
ProfTalks · 26:39

Nitrosamines risk assessment: why?
Fernanda Waechter · 2:58

Emerging Opportunities in Business, Business Organization (NEP Batch)
ProfTalks: Commerce Era · 41:16

Overview of the Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs
U.S. Food and Drug Administration · 1:22:14

Human Activity lect-01 Class XI Accounts.
ProfTalks: Commerce Era · 25:34

Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
Emery Pharma · 36:41

What is Accounting ? Explained in 5 Minutes.
ProfTalks: Commerce Era · 5:37

A Complete Guide to Nitrosamine Impurity Regulatory Limits
ResolveMass Laboratories Inc. · 6:59

Introduction To Accounting|| Part 2 || Basic Accouting || Class XI || All Board || BY GAUTAM SIR
ProfTalks: Commerce Era · 8:40

How to Decide the Need of Testing Nitrosamine Impurities into Pharmaceuticals?
Pharma Growth Hub · 8:35